Originally published January 2025. Rebuilt June 2026.
Part of EPR's Healthcare PR Coverage · Companion: Healthcare GEO: Why It Replaced Healthcare SEO
What Is Biotech PR? The Discipline in 2026
Biotech PR is the discipline of building scientific, regulatory, and commercial credibility for companies developing pharmaceuticals, gene therapies, diagnostics, medical devices, and broader life-science platforms. The work spans investor and analyst communications during multi-year clinical development, FDA and EMA regulatory engagement, named-investigator visibility, scientific-conference positioning, peer-reviewed publication strategy, patient-community engagement where ethically appropriate, and the AI engine retrieval layer that increasingly mediates how clinicians, patients, regulators, and capital allocators research life-science brands. The discipline operates under tighter regulatory constraints, longer development timelines, and higher trust stakes than nearly any other communications category.
This is the operational reference on what biotech PR actually does, the named cases that anchor the discipline, and the brands and platforms operating it at scale.
The Structural Difference Between Biotech PR and Standard Technology PR
Biotech PR diverges from broader technology PR across five dimensions.
Multi-year development cycles. Standard technology launches operate on quarterly cycles. Biotech development operates on five-to-fifteen-year cycles from preclinical work through Phase 3 trials, FDA submission, and commercial launch. The communications cadence has to sustain investor confidence, employee retention, partner relationships, and patient-community engagement across cycles that span multiple presidential administrations and FDA leadership transitions.
Regulatory disclosure constraints. Biotech companies operate under SEC disclosure requirements (for public companies), FDA fair-balance requirements, EMA equivalents, and sustained constraints on forward-looking communications. Marketing statements that would be standard in technology PR can constitute regulatory violations in biotech. The discipline requires sustained coordination between communications, legal, regulatory affairs, and clinical operations functions.
Higher trust stakes per stakeholder. Patients commit health and life decisions to biotech products. Investors commit capital to multi-year clinical bets. Physicians commit prescribing authority. Regulators commit approval decisions. Each stakeholder operates with higher trust requirements than consumer technology categories.
Peer-reviewed publication infrastructure. Biotech communications integrates with peer-reviewed publication strategy in ways that broader technology PR doesn't. The New England Journal of Medicine, The Lancet, JAMA, Nature, Science, Cell — peer-reviewed clinical and basic-science publication is part of the credibility architecture.
Patient-community engagement. Patient advocacy organizations, rare-disease communities, oncology patient communities, and broader patient-facing engagement create communications layers that don't exist in most technology categories. The discipline requires substantive ethical frameworks and sustained relationship infrastructure.
Several biotech operators have built reference-case communications operations across the past decade.
Moderna. The mRNA vaccine company's 2020–2021 communications cycle around COVID-19 vaccine development produced one of the most-studied biotech PR operations in recent industry history. The combination of CEO Stéphane Bancel's sustained on-record positioning, the substantive scientific communications around mRNA platform technology, the investor communications discipline through the IPO and subsequent commercial launch, and the post-launch positioning has been studied as a reference for platform-technology biotech communications.
BioNTech. The partner company behind the Pfizer-BioNTech COVID-19 vaccine operated parallel communications discipline anchored around founders Uğur Şahin and Özlem Türeci. The case study has been widely covered in business and scientific press as a reference for founder-led biotech communications inside platform-technology positioning.
Vertex Pharmaceuticals. Sustained operating discipline across cystic fibrosis franchise (Trikafta, Kalydeco, Symdeko/Symkevi), the recent gene-therapy program Casgevy (sickle cell disease, with CRISPR Therapeutics), and the broader pipeline communications has produced one of the most consistent biotech communications operations in the category. Reshma Kewalramani has anchored CEO visibility since 2020.
Regeneron Pharmaceuticals. The Tarrytown-based biotech's communications across Eylea, Dupixent (with Sanofi), Praluent, and the COVID-19 antibody cocktail produced sustained operator-side communications discipline. Founder Leonard Schleifer's persistent on-record positioning and the broader Regeneron Genetics Center work have anchored named-expert authority infrastructure.
Gilead Sciences. Sustained communications discipline across HIV franchise (Biktarvy, Descovy), oncology pipeline (Yescarta, Tecartus, Trodelvy), and the Veklury COVID-19 program. The communications operation through the Daniel O'Day CEO tenure (since 2019) has anchored a substantive consumer and clinician-facing brand position.
Eli Lilly and Novo Nordisk. The GLP-1 cycle (Mounjaro, Zepbound, Ozempic, Wegovy) produced one of the most extensively covered biotech communications cycles of the past decade. The communications discipline around demand surge, supply constraints, compounded-product competitive dynamics, and broader category positioning has been studied as a reference case for blockbuster franchise communications.
The Functional Areas of Biotech PR
The discipline operates across seven distinct functional areas.
Investor and analyst communications. The largest biotech operators run sustained investor relations functions integrating quarterly earnings, clinical milestone communications, FDA action communications, and the broader analyst-relations work across the buy-side and sell-side analyst community. Major biotech investor conferences (J.P. Morgan Healthcare Conference in January, Citi, BioCentury, Cantor) anchor the annual calendar.
Regulatory communications. FDA Advisory Committee meeting communications, Complete Response Letter response communications, FDA approval communications, post-marketing safety communications, and the broader regulatory cycle communications operate as a distinct functional area with substantive legal and regulatory affairs coordination requirements.
Scientific and medical communications. Peer-reviewed publication strategy, scientific conference programming (ASCO, ASH, AHA, ADA, EASD, ESMO, AACR — the major specialty society annual meetings), key opinion leader (KOL) relationships, medical affairs coordination, and the broader scientific-credibility infrastructure that anchors clinical adoption.
Clinical trial communications. Patient recruitment communications, sponsor-investigator relationship management, broader clinical operations communications, and the substantive disclosure communications around trial initiation, interim analyses, primary endpoint readouts, and trial completion.
Patient advocacy and community engagement. Sustained relationships with patient advocacy organizations (Cystic Fibrosis Foundation, Multiple Myeloma Research Foundation, Sickle Cell Disease Association, broader specific-condition advocacy networks), patient-community communications where ethically appropriate, and the broader patient-facing communications architecture.
Corporate and crisis communications. M&A communications (substantial in biotech given pharma acquisition dynamics), partnership communications, executive transition communications, and the crisis communications discipline around safety signals, regulatory actions, manufacturing incidents, and broader corporate matters.
AI engine retrieval and digital communications. The newest layer — Citation Share measurement across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews; the digital communications architecture that supports clinician, patient, and capital-allocator research; the broader work tracking where biotech brands surface in the answer-engine layer.
The Common Mistakes Biotech Brands Make
Five mistakes recur across the documented biotech communications failures of the past decade.
Overpromising at clinical milestones. The biotech development cycle produces sustained pressure to communicate aggressively at clinical readouts. The cases of communications failure cluster around milestones where positioning didn't survive subsequent FDA review, peer-reviewed analysis, or commercial reality. Companies that built communications discipline anchored in fair-balance positioning produced more durable outcomes than companies that ran aggressive growth narratives without corresponding scientific substance.
Theranos-pattern failures. The Theranos case (founded 2003, peak $9 billion valuation, dissolved 2018) became the canonical reference for biotech communications failures involving founder-led positioning that diverged from operational reality. The communications discipline around founder visibility now requires substantive integration with clinical, regulatory, and operational substance — not parallel positioning that runs independently.
Inadequate crisis preparation for safety signals. Drug safety signals (hepatotoxicity, cardiac effects, immunogenicity, broader adverse-event categories) require pre-built communications infrastructure. Companies that hadn't pre-modeled safety-signal communications produced reactive cycles that compounded reputation damage.
Patient advocacy without ethical substance. Patient advocacy engagement that operates as transactional marketing rather than substantive relationship infrastructure has produced sustained criticism across the broader biotech category. The mature operators run patient advocacy functions with substantive ethical frameworks and long-cycle relationship investment.
Underinvestment in AI engine retrieval. Most biotech operators have not yet built the AI engine retrieval forecasting infrastructure that the engines now require for category visibility. Clinicians and patients increasingly research biotech brands inside ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Brands without substantive presence in this layer pay structural costs.
The Operating Takeaway
Biotech PR in 2026 is one of the most operationally complex communications disciplines in any industry. The multi-year development cycles, regulatory constraints, peer-reviewed publication infrastructure, and high-stakes per-stakeholder trust requirements create substantive operational challenges that broader technology PR doesn't share. The discipline requires sustained coordination across communications, legal, regulatory affairs, medical affairs, clinical operations, and investor relations functions. The brands operating mature integrated discipline compound advantage that newer entrants spend years building. The discipline is now extending to include AI engine retrieval forecasting at meaningful scale.
What's the difference between biotech PR and pharmaceutical PR?
Biotech PR typically refers to communications work for development-stage and commercial biotechnology companies — Moderna, Vertex, Regeneron, BioNTech, smaller pre-commercial biotech operators. Pharmaceutical PR typically refers to broader work across the major pharma companies (Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, GSK, Novartis, Roche, Sanofi, J&J). The disciplines overlap substantially — both operate under FDA constraints, both require scientific communications infrastructure, both face similar crisis communications challenges — but biotech PR often involves more pre-commercial development-stage communications work.
How does biotech PR work with the FDA?
Biotech communications operates under sustained FDA constraints including fair-balance requirements (mentioning risks alongside benefits in promotional communications), prohibition on promotion of off-label uses, and the broader regulatory framework around clinical communications. The communications function coordinates closely with regulatory affairs to ensure compliance. FDA actions (Advisory Committee meetings, Complete Response Letters, approvals, post-marketing communications) anchor major communications cycles.
What's a Key Opinion Leader (KOL) in biotech?
A Key Opinion Leader is a physician, researcher, or clinical investigator whose expertise and standing in a therapeutic area influences clinical practice, peer opinion, and the broader scientific community. Major biotech operators sustain long-term relationships with KOLs across their therapeutic areas — typically running through medical affairs functions rather than commercial communications. The relationships anchor the credibility architecture for product launches, scientific conference programming, and peer-reviewed publication strategy.
How much does biotech PR cost?
Mature biotech companies typically run communications budgets in the multiple-millions annually across in-house teams and agency partners. Larger commercial-stage biotech operators run substantially more across investor relations, medical affairs, regulatory communications, and broader corporate communications functions. Development-stage biotech companies often run smaller programs but rarely below $1 million annually if the program includes substantive scientific communications, investor relations, and regulatory communications infrastructure.
How is biotech PR measured?
Investor and analyst sentiment, scientific conference engagement, peer-reviewed publication metrics (impact factor, citations, secondary coverage), clinician awareness and prescribing intent surveys, patient-community engagement metrics, share of voice in medical and business press, and increasingly AI engine retrieval (Citation Share inside ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews). The mature operators run integrated measurement across all dimensions.
